Reagents and methods for use in cancer diagnosis, classification and therapy
View Patent ↗Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
1. A method of assessing a prognosis of a patient having a breast tumor, the method comprising steps of:
obtaining a tumor sample from a patient having a breast tumor;
contacting the tumor sample with a panel of antibodies that includes an antibody that binds to HTF9C and at least one antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5, wherein each of the at least one antibodies binds to a different biomarker within the group; and
assessing the patient's likely prognosis based upon a pattern of binding or lack of binding of the panel to the tumor sample, wherein across a population of patients with breast tumors, a higher level of binding of the antibody that binds to HTF9C correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence, and a higher level of binding of the at least one antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, NDRG1, and CEACAM5 correlates with a higher likelihood that the patient will die from breast cancer or have a recurrence.
2. The method of claim 1 wherein the step of assessing comprises assessing the likelihood that the patient will die from breast cancer.
3. The method of claim 1 wherein the step of assessing comprises assessing the likelihood that the patient will have a recurrence.
4. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C;
a second antibody that binds to a first biomarker selected from the group consisting of p53, NDRG1, SLC7A5 and CEACAM5; and
a third antibody that binds to a second biomarker selected from the group consisting of p53, NDRG1, SLC7A5 and CEACAM5, wherein the first and second biomarkers are different.
5. The method of claim 4 wherein the panel further includes:
a fourth antibody that binds to a third biomarker selected from the group consisting of p53, NDRG1, SLC7A5 and CEACAM5, wherein the first, second and third biomarkers are different.
6. The method of claim 5 wherein the panel further includes:
a fifth antibody that binds to a fourth biomarker selected from the group consisting of p53, NDRG1, SLC7A5 and CEACAM5, wherein the first, second, third and fourth biomarkers are different.
7. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C; and
a second antibody that binds to p53.
8. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C; and
a second antibody that binds to NDRG1.
9. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C; and
a second antibody that binds to SLC7A5.
10. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C; and
a second antibody that binds to CEACAM5.
11. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C, and
a second antibody that binds to a biomarker selected from the group consisting of SLC7A5, NDRG1, and CEACAM5.
12. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C, and
a second antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, and CEACAM5.
13. The method of claim 1 wherein the panel includes:
a first antibody that binds to HTF9C, and
a second antibody that binds to a biomarker selected from the group consisting of SLC7A5, p53, and NDRG1.